Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 2Sarcoma 1Neoplasms 1Muscle Neoplasms 1HIV Infections 1Acquired Immunodeficiency Syndrome 1AIDS-Related Complex 1

Interventions

Doxorubicin 20Cyclophosphamide 18Radiotherapy 17Ifosfamide 13Vincristine 12Magnetic Resonance Spectroscopy 12Specimen Handling 11Biopsy 10Etoposide 9Filgrastim 8Dactinomycin 8X-Rays 6Temozolomide 6Sirolimus 6Phantoms, Imaging 6Melphalan 6temsirolimus 5cixutumumab 5Thalidomide 5Celecoxib 5Sorafenib 4Radiation 4Nuclear Medicine Department, Hospital 4Ipilimumab 4Fluorodeoxyglucose F18 4Chemotherapy, Adjuvant 4Carboplatin 4pazopanib 3ixabepilone 3cabozantinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Sarcoma × Tumor Necrosis Factor-alpha × Clear all
NCT00019968 2023-10-31

Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
Sarcoma

Neoplasms, Sarcoma, Muscle Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡